• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 3. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzene and substituted derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives

Recent Advances in the Application of trans-1,2-Bis(diphenylphosphino)ethylene (CAS: 983-81-3) in Chemical Biology and Pharmaceutical Research

trans-1,2-Bis(diphenylphosphino)ethylene (CAS: 983-81-3), commonly referred to as dppe, is a widely utilized bidentate phosphine ligand in coordination chemistry and catalysis. Recent studies have highlighted its expanding role in chemical biology and pharmaceutical research, particularly in the development of novel metal complexes for therapeutic applications. This research brief synthesizes the latest findings on the structural, catalytic, and biological properties of dppe-based compounds, with a focus on their potential in drug discovery and targeted therapies.

A 2023 study published in Journal of Medicinal Chemistry demonstrated the efficacy of dppe-derived palladium(II) complexes as anticancer agents. These complexes exhibited selective cytotoxicity against triple-negative breast cancer (TNBC) cell lines, with IC50 values in the low micromolar range. Mechanistic studies revealed that the compounds induce apoptosis via mitochondrial dysfunction and ROS generation, while the trans-chelating geometry of dppe was found to be critical for maintaining stability under physiological conditions.

In the field of antimicrobial research, novel silver(I)-dppe complexes have shown remarkable activity against multidrug-resistant Staphylococcus aureus (MRSA) strains. The unique electronic properties imparted by the dppe ligand were shown to enhance membrane penetration and disrupt bacterial biofilms more effectively than conventional antibiotics. These findings, reported in ACS Infectious Diseases, suggest promising avenues for combating antibiotic resistance.

Recent advancements in catalytic applications include the development of dppe-containing ruthenium catalysts for asymmetric hydrogenation reactions. A 2024 Nature Catalysis paper detailed how the rigid backbone of dppe enables precise control of stereoselectivity in the synthesis of chiral pharmaceutical intermediates, achieving enantiomeric excesses >99% for certain β-amino acid derivatives. This breakthrough has significant implications for the production of enantiopure drugs.

Structural studies utilizing X-ray crystallography and DFT calculations have provided new insights into the coordination behavior of dppe. The ligand's ability to adopt varying bite angles (74-85°) depending on metal center and oxidation state has been correlated with catalytic activity in cross-coupling reactions relevant to pharmaceutical synthesis. These findings were recently compiled in a comprehensive review in Coordination Chemistry Reviews.

From a drug delivery perspective, dppe-modified gold nanoparticles have emerged as versatile platforms for targeted therapy. The phosphine groups facilitate stable gold-phosphine bonds while allowing surface functionalization with targeting moieties. Recent in vivo studies demonstrate improved tumor accumulation and reduced off-target effects compared to traditional delivery systems, as reported in Biomaterials Science.

Ongoing clinical investigations are exploring dppe-containing radiopharmaceuticals for diagnostic imaging. The chelating properties of dppe enable stable complexation with various radioisotopes (e.g., 99mTc, 64Cu), while its hydrophobicity can be modulated for optimal biodistribution. Preliminary results from Phase I trials show promising tumor-to-background ratios for prostate cancer detection.

Future research directions highlighted in recent literature include: (1) development of dppe-based PROTACs (proteolysis targeting chimeras) for targeted protein degradation, (2) exploration of dppe-metal complexes as photosensitizers for photodynamic therapy, and (3) computational design of dppe derivatives with tailored electronic properties for specific therapeutic applications. The unique combination of stability, tunability, and biological activity positions dppe as a versatile scaffold for next-generation pharmaceutical development.

• 5044-52-0(Triphenylvinylphosphonium Bromide)
• 17427-91-7(Phosphine, 1,2-ethenediylbis[diphenyl- (en))
• 26681-88-9(Phenyldivinylphosphine)
• 983-80-2((Z)-1,2-Bis(diphenylphosphino)ethene)
• 54770-27-3(1,2-vinylenebis(triphenylphosphonium) dibromide)
• 2155-96-6(Diphenyl(vinyl)phosphine)
• 102532-71-8(Copper(1+),bis[1,2-ethenediylbis[diphenylphosphine-kP]]-, chloride, (T-4)- (9CI))
• 116449-44-6(Gold(1+),bis[1,2-ethenediylbis[diphenylphosphine]-P,P']-, (T-4)- (9CI))
• 54599-99-4(triphenyl(propadienyl)phosphonium)
• 54770-15-9(Phosphonium, 1,2-ethenediylbis[triphenyl-, diiodide)